Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval

Mar 30 2017

• By Derrick Gingery

OvarianCancer_1200x675

Related Content

Birth Of A Biomarker? FDA Doesn't Define Eosinophilic Asthma, Defers To Docs On Nucala

Mar 21 2016

AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

Mar 15 2017

Bristol-Myers wins US Opdivo approval three months early

Dec 23 2014

Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer

Mar 28 2017

Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission

Nov 04 2016

Clovis Transitions To Commercial Stage On Rubraca Approval

Dec 20 2016

Related Companies

Tesaro, Inc.

Myriad Genetics, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

GSK plc

AstraZeneca PLC

Clovis Oncology, Inc.

Additional Topics

United States Approvals Regulation FDA Cancer BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window